Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer

被引:3
|
作者
Conces, Madison L. [1 ]
Mahipal, Amit [1 ]
机构
[1] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA
关键词
rectal cancer; neoadjuvant therapy; chemotherapy; TOTAL MESORECTAL EXCISION; POSTOPERATIVE ADJUVANT CHEMOTHERAPY; COURSE PREOPERATIVE RADIOTHERAPY; CLINICAL COMPLETE RESPONDERS; MEDIAN FOLLOW-UP; QUALITY-OF-LIFE; COLORECTAL-CANCER; INTERNATIONAL WATCH; SEXUAL DYSFUNCTION; RANDOMIZED-TRIAL;
D O I
10.3390/curroncol31010024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Local and metastatic recurrence are primary concerns following the treatment of locally advanced rectal cancer (LARC). Chemoradiation (CRT) can reduce the local recurrence rates and has subsequently moved to the neoadjuvant setting from the adjuvant setting. Pathological complete response (pCR) rates have also been noted to be greater in patients treated with neoadjuvant CRT prior to surgery. The standard approach to treating LARC would often involve CRT followed by surgery and optional adjuvant chemotherapy and remained the treatment paradigm for almost two decades. However, patients were often unable to complete adjuvant chemotherapy due to a decreased tolerance of chemotherapy following surgery, which led to upfront treatment with both CRT and chemotherapy, and total neoadjuvant therapy, or TNT, was created. The efficacy outcomes of local recurrence, disease-free survival, and pCR have improved in patients receiving TNT compared to the standard approach. Additionally, more recent data suggest a possible improvement in overall survival as well. Patients with a complete clinical response following TNT have the opportunity for watch-and-wait surveillance, allowing some patients to undergo organ preservation. Here, we discuss the clinical trials and studies that led to the adoption of TNT as the standard of care for LARC, with the possibility of watch-and-wait surveillance for patients achieving complete responses. We also review the possibility of overtreating some patients with LARC.
引用
收藏
页码:366 / 382
页数:17
相关论文
共 50 条
  • [31] What Predicts Complete Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer?
    Yilmaz, Sumeyye
    Liska, David
    Conces, Madison
    Tursun, Naz
    Elamin, Doua
    Ozgur, Ilker
    Maspero, Marianna
    Rosen, David
    Khorana, Alok
    Balagamwala, Ehsan
    Amarnath, Sudha
    Valente, Michael
    Steele, Scott
    Krishnamurthi, Smitha
    Gorgun, Emre
    DISEASES OF THE COLON & RECTUM, 2025, 68 (01) : 60 - 68
  • [32] Chemoimmunotherapy in the context of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer
    Shamseddine, A.
    Turfa, R.
    Elias, C.
    Kattan, J.
    Mukherji, D.
    Temraz, S.
    Alqasem, K.
    Amarin, R.
    Al Awabdeh, T.
    Deeba, S.
    Mohamad, I.
    Daoud, F.
    Al Masri, M.
    Dabous, A.
    Hushki, A.
    Jaber, O.
    Charafeddine, M.
    Al Darazi, M.
    Zeidan, Y.
    Geara, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S339 - S339
  • [33] Correction to: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial
    Martin R. Weiser
    Annals of Surgical Oncology, 2022, 29 : 3886 - 3886
  • [34] Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: How to Select the Most Suitable?
    Bandidwattanawong, Chanyoot
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [35] Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care?
    Hong, Theodore S.
    Ryan, David P.
    JAMA ONCOLOGY, 2018, 4 (06)
  • [36] Total Neoadjuvant Therapy Decreases Time to Ileostomy Reversal for Locally Advanced Rectal Cancer
    Spencer, Shannon B.
    Abelson, Jonathan
    Kleiman, David A.
    DISEASES OF THE COLON & RECTUM, 2022, 65 (09) : E914 - E914
  • [37] Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer
    Gollins, S.
    Sebag-Montefiore, D.
    CLINICAL ONCOLOGY, 2016, 28 (02) : 146 - 151
  • [38] Intensifying neoadjuvant treatment in locally advanced rectal cancer
    Patel, Swapnil
    Kapoor, Akhil
    LANCET ONCOLOGY, 2021, 22 (07): : E301 - E301
  • [39] Total neoadjuvant therapy approach for the treatment of locally advanced rectal cancer. Where do we stand?
    Romero Zoghbi, Sigfredo Elias
    Martin, Margarita Martin
    Garcia, Juan Carlos
    Valero, Mireia
    Rincon, Diego
    Pena Huertas, Marina
    Fusco, Juan Pablo
    Lopez, Escarlata
    Zafra, Juan
    Fernandez Luengas, David
    Campos, Fernando Lopez
    Counago, Felipe
    ONCOLOGY, 2024, 102 (07) : 646 - 657
  • [40] Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?
    Scott, Aaron J.
    Kennedy, Erin B.
    Gholami, Sepideh
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)